This reality show is short on scandal, betrayal and tears, and has an unusual aim: Elevating U.S. manufacturing.

Spine BioPharma's randomised Phase III MODEL trial assessing the transforming growth factor beta (TGF-β) antagonist, SB-01, ...

Up to one in 20 people in boroughs across England and Wales are immigrants who arrived in the UK in 2024, new analysis ...

Kameda Seika Co., Ltd. ( ($JP:2220) ) has issued an update. Kameda Seika Co., Ltd. announced a correction to its previously released consolidated ...

The current quarter saw a significant unrealized loss related to Tilson, with a $9.5 million writedown and a reduction in portfolio value to $52.4 million from $62 million at the end of Q1. Net asset ...

A new study highlights the risks of atopic dermatitis flare-ups after discontinuing dupilumab and the likelihood of ...

New research shows people prefer partners whose sexual history shows signs of settling down, even if they've had many ...

Lattice Semiconductor Corporation (Nasdaq: LSCC), the low power programmable leader, announced financial results today for ...

After Earth’s greatest extinction, it wasn’t just volcanic fury that kept the planet hot; it was the death of tropical ...

The process of planning and maintaining an optimal route network is complex. It requires consideration of various factors.

New York-based Spine BioPharma on Friday revealed disappointing results with its growth factor beta (TGF-β) antagonist, SB-01 ...

In negotiation, the first number often carries disproportionate weight. While perhaps not always an absolute guarantee of victory, the concept ...